Now on opnMe: Elucidate the role of HSD17B13 using BI-3231, a potent and selective HSD17B13 inhibitor
06 February 2023
Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) a lipid-droplet associated enzyme, is a member of the HSD17B family and is most abundantly expressed in hepatocytes. Though its exact role and substrates are unknown, its expression profile raises questions beyond its biological function in hepatocytes. We are now pleased to offer you free access to BI-3231, a potent and selective HSD17B13 inhibitor for in vitro as well as in vivo studies, as part of our commitment to open science.
BI-3231 is active on both the human and mouse homologs of HSD17B13, displaying potencies in the low nanomolar range. It also presents good selectivity against other members of the HSD17B family, including HSD17B11 which has a high degree of sequence similarity with HSD18B13. The methylated analog of BI-3231, which shows no activity in the same in vitro assays, is likewise provided free of charge as a negative control, under the designation BI-0955.
We invite you to discover new biology and shed light into the function of HSD17B13 with BI-3231 and its negative control BI-0955. The molecules will be shipped to you anywhere in the world for free. You will own all results you will generate with the molecules and may use them for your own publications.
No registration needed
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About BI-3231:
BI-3231 is a potent inhibitor of human and mouse HSD17B13 and is highly selective over other HSD17B family members, including HSD17B11. Its binding to HSD17B13 is dependent on the presence of NAD+ and has been confirmed by a strong temperature shift in a human HSD17B13 thermal shift assay. BI-3231 has been extensively characterized in vitro as well as in vivo and its mode of inhibition has been elucidated. BI-0955 is available as its negative control.
About opnMe:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions via our “Molecules for Collaboration” calls. As part of our third pillar, our “opn2EXPERTS” program, we also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.